Sitagliptin is the first dipeptidylpeptidase-4 inhibitor to be used in the management of type 2 diabetes. It is widely used as an add-on therapy to ongoing management or as monotherapy where it is deemed necessary. It has been found to be beneficial in improving β-cell function and glycemic control, and also is used in special circumstances like chronic kidney disease, with appropriate dose red...

A 65‐year‐old female presented with a 2‐year history of recurrent, asymptomatic, tense blisters on her feet. There was no history of any repeated trauma, exposure to chemicals, insect bite, or any constitutional symptoms. She previously had similar lesions on her arms, back, and buttocks, however, they healed spontaneously. She had a history of uncontrolled type 2 DM for the past 20 years, for ...

We examined the histological changes of the pancreas in a 75-year-old diabetic woman who was treated with sulphonylurea for 10 years and required insulin treatment for the subsequant 10 years. She was positive for antiglutamic acid decarboxylase antibody (GAD Ab) 20 years after the diagnosis of diabetes. Her autopsied pancreas revealed disfigured islets and no beta cells. These changes were ind...

Materials and methods This is a prospective, intervention, non-randomized, phase IV study. We included patients over 60 yrs. old, both sexes, with HbA1c>8.5% using oral hypoglycemic agents and insulin (IN), then we replaced SY by PD. IN used were NPH and Regular, all patients have received a blood glucose monitor, lancet tapes, capillary blood glucose tests (3 tests/day). HbA1c was measured at ...

OBJECTIVE The aim of this study is to compare lipid and lipoprotein (a) profiles in patients with type 2 diabetes mellitus (DM) on insulin and oral hypoglycemic therapy. METHODS The study took place in the Department of Physiology, Army Medical College, Rawalpindi, Pakistan, during 2002. Ninety-seven type 2 DM patients participated in the study. We divided the patients according to the type o...

BACKGROUND There are variable recommendations regarding initiating monotherapy or dual therapy in patients with newly diagnosed type 2 diabetes (T2D). Clear initial strategies are of particular importance in underserved settings where access to care and financial burdens are significant barriers. OBJECTIVES To provide descriptive data of metabolic outcomes to therapy regimens for low-income i...

OBJECTIVE Clinical trials provide information regarding the safety and efficacy of medications used to manage type 2 diabetes but do not elucidate drug effectiveness in a typical managed care environment. The aim of this study was to characterize "real-world" drug utilization patterns from both a prescriber and a patient perspective. RESEARCH DESIGN AND METHODS We conducted a retrospective an...

Sodium-glucose cotransporter 2 inhibitors are a new class of oral hypoglycemic agents, and thus safety data are limited. We present a 48-year-old woman with type 2 diabetes mellitus and Child's Class A cirrhosis secondary to nonalcoholic steatohepatitis presenting with jaundice and acute cholestatic liver injury. Other than starting dapagliflozin, she reported no medication changes or supplemen...

Objectives Assess the degree of understanding of diabetes without appropriate control in elderly patients. Materials and methods: We performed a Cross study of diabetic patients in the Endocrinology Department of a Brazilian tertiary hospital who were treated between June and December 2014. We include patients over 60 yrs. of age, of both sexes, with HbA1c ≥ 8.5% using oral hypoglycemic agents ...

Gestational diabetes mellitus (GDM) is a serious and frequent concern in pregnancy. Worldwide, the prevalence of GDM ranges from 8 to 20%. In 5% cases, this pathology accompanied by complications such as diabetic fetopathy, preeclampsia, neonatal hypoglycemia, hyperbilirubinemia. Modern national foreign guidelines for detecting hyperglycemia during pregnancy diagnosing recommend lifestyle chang...